Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash sales
The Big Market Report Take
If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
- Silver Price Steadies At $70 While Bond Yields Stay Firm After Fed HoldSeeking Alpha13m ago
- EFAA: Collect An 8.3% Yield From Global EquitiesSeeking Alpha15m ago
- Richemont: The Market Has Likely Front-Run Its Risks, An Entry Point Has EmergedSeeking Alpha18m ago